Hepatic safety profi le of fosamprenavir-containing regimens in HIV-1-infected patients with or without hepatitis B or C coinfection

HIV Clinical Trials

Volumn 13, Issue 3, 2012, Pages 171-177

  Ha, B ^a   Wine, B ^a   Rodriguez Alcantra, F ^b   Shaefer, M ^b  

^a GLAXOSMITHKLINE   (United States)

^b VIIV HEALTHCARE   (United States)

Author keywords

fosamprenavir; HBV; HCV; hepatitis B; hepatitis C; HIV

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; FOSAMPRENAVIR; RITONAVIR; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; CARBAMIC ACID DERIVATIVE; ORGANOPHOSPHATE; SULFONAMIDE;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; DIARRHEA; DRUG HYPERSENSITIVITY; DRUG SAFETY; FEMALE; HEPATITIS B; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; NAUSEA; POST HOC ANALYSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SIDE EFFECT; TREATMENT DURATION; ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADOLESCENT; BLOOD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG COMBINATION; DRUG EFFECT; HUMAN IMMUNODEFICIENCY VIRUS 1; LIVER; MIDDLE AGED; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADOLESCENT; ADULT; AGED; ALANINE TRANSAMINASE; ANTI-HIV AGENTS; ASPARTATE AMINOTRANSFERASES; CARBAMATES; COINFECTION; DRUG THERAPY, COMBINATION; FEMALE; HEPATITIS B; HEPATITIS C; HIV-1; HUMANS; LIVER; MALE; MIDDLE AGED; PHOSPHORIC ACID ESTERS; PROSPECTIVE STUDIES; SULFONAMIDES;

EID: 84864306516     PISSN: 15284336     EISSN: 19455771     Source Type: Journal    
DOI: 10.1310/hct1303-171     Document Type: Article

References (25)

1. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. January 10, 2011; 1-166. http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL. pdf. Accessed May 24, 2011.
2. Sulkowski MS, Thomas DL, Chaisson RE, Moore RD. Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodefi ciency virus and the role of hepatitis C or B virus infection. JAMA. 2000;283:74-80. (Pubitemid 30038386)
3. Nunez M, Lana R, Mendoza JL, et al. Risk factors for severe hepatic injury after introduction of highly active antiretroviral therapy. J Aquir Immune Defic Syndr. 2001;27:426-431. (Pubitemid 32801070)
4. Nunez M. Hepatotoxicity of antiretrovirals: incidence, mechanisms and management. J Hepatol. 2006;44:S132-S139. (Pubitemid 43053889)
5. Kandula V, Khanlou H, Farthing C. Tipranavir: a novel second-generation non-peptidic protease inhibitor. Expert Rev Anti Infect Ther. 2005;3:9-21. (Pubitemid 40277835)
6. Sulkowski MS, Mehta SH, Chaisson RE, Thomas DL, Moore RD. Hepatoxicity associated with protease inhibitor-based antiretroviral regimens with or without concurrent ritonavir. AIDS. 2004;18:2277-2284. (Pubitemid 39620220)
7. Perez-Elias MJ, Sanchez-Conde M, Soriano V, et al. Fosamprenavir (GW433908)/ritonavir in HIV-infected patients: efficacy and safety results from the Spanish Expanded Access Program. Enferm Infecc Microbiol Clin. 2009;27:28-32.
8. Pineda JA, Perez-Elias M-J, Pena JM, Luque I, Rodriguez-Alcantara F. Low rate of adverse hepatic events associated with fosamprenavir/ritonavir-based antiretroviral regimens. HIV Clin Trials. 2008;9:309-313.
9. Gathe JC Jr, Ive P, Wood R, et al. SOLO: 48-week effi cacy and safety comparison of once-daily fosamprenavir/ritonavir versus twice-daily nelfi navir in naive HIV-1-infected patients. AIDS. 2004;18:1529-1537. (Pubitemid 39037477)
10. Eron J Jr, Yeni P, Gathe J Jr, et al. The KLEAN study of fosamprenavir-ritonavir versus lopinavir-ritonavir, each in combination with abacavir-lamivudine, for initial treatment of HIV infection over 48 weeks: a randomised non-inferiority trial. Lancet. 2006;368:476-482. Erratum in Lancet. 2006;368:1238. (Pubitemid 44160731)
11. Cohen C, DeJesus E, LaMarca A, et al. Similar virologic and immunologic effi cacy with fosamprenavir boosted with 100 mg or 200 mg of ritonavir in HIV-infected patients: results of the LESS trial. HIV Clin Trials. 2010;11:239-247.
12. Young B, DeJesus E, LaMarca A, et al. Switching to fosamprenavir (FPV) led to similar efficacy and safety in HIV-1-infected subjects on their first PI regimen: a prospective, open-label, multicenter, randomized trial (ESS100290). Presented at: 17th International AIDS Conference, August 3-8, 2008, Mexico City, Mexico. Poster TUPE0067.
13. Hicks CB, DeJesus E, Sloan LM, et al. Comparison of once-daily fosamprenavir boosted with either 100 or 200 mg of ritonavir, in combination with abacavir/lamivudine: 96-week results from COL100758. AIDS Res Hum Retroviruses. 2009;25:395-403.
14. Smith KY, Weinberg WG, DeJesus E, et al. Fosamprenavir or atazanavir once daily boosted with ritonavir 100 mg, plus tenofovir/emtricitabine, for the initial treatment of HIV infection: 48-week results of ALERT. AIDS Res Ther. 2008;5:5.
15. Kumar P, De Jesus E, Huhn G, et al. SUPPORT (Study in Underrepresented Patient Populations of Regimen Tolerability): 48-week results of fosamprenavir/ritonavir versus efavirenz with abacavir/lamivudine in antiretroviral-naïve subjects. Presented at: Tenth International Congress on Drug Therapy in HIV Infection, November 7-11, 2010; Glasgow, Scotland. Poster P7.
16. Wai C-T, Greenson JK, Fontana RJ, et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology. 2003;38:518-526. (Pubitemid 36919874)
17. Macias J, Giron-Gonzalez JA, Gonzalez-Serrano M, et al. Prediction of liver fi brosis in HIV/HCV-coinfected patients by simple noninvasive indexes. Gut. 2006;55:409-414. (Pubitemid 43268282)
18. Mikl J, Sulkowski MS, Benhamou Y, et al. Hepatic profi le analyses of tipranavir in phase II and III clinical trials. BMC Infect Dis. 2009;9:203-213.
19. Fourie J, Flamm J, Rodriguez-French A, et al. Effect of baseline characteristics on the efficacy and safety of once-daily darunavir/ritonavir in HIV-1-infected, treatmentnaïve ARTEMIS patients at week 96. HIV Clin Trials. 2011;12:313-322.
20. Rachlis A, Clotet B, Baxter J, Murphy R, Lefebvre E. Safety, tolerability, and effi cacy of darunavir (TMC114) with low-dose ritonavir in treatment-experienced, hepatitis B or C co-infected patients in POWER 1 and 3. HIV Clin Trials. 2007;8:213-220. (Pubitemid 47327458)
21. Reyataz (atazanavir sulfate). Prescribing information. Bristol-Myers Squibb; 2010.
22. Murphy RL, Sanne I, Cahn P, et al. Dose-ranging, randomized, clinical trial of atazanavir with lamivudine and stavudine in antiretroviral-naïve subjects: 48-week results. AIDS. 2003;17:2603-2614. (Pubitemid 38402338)
23. Squires K, Lazzarin A, Gatell JM, et al. Comparison of once-daily atazanavir with efavirenz, each in combination with fi xed-dose zidovudine and lamivudine, as initial therapy for patients infected with HIV. J Acquir Immune Defi c Syndr. 2004;36:1011-1019. (Pubitemid 38989366)
24. Molina J-M, Andrade-Villanueva J, Echevarria J, et al. Once-daily atazanavir/ritonavir compared with twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 96-week efficacy and safety results of the CASTLE study. J Acquir Immune Defi c Syndr. 2010;53:323-332.
25. Johnson M, Grinsztejn B, Rodriguez C, et al. 96-week comparison of once-daily atazanavir/ritonavir and twicedaily lopinavir/ritonavir in patients with multiple virologic failures. AIDS. 2006, 20:711-718. (Pubitemid 43884298)